To assess the role of expression of the DSG2 and CD46 receptors on ONCOS‐102 treatment of patients with solid tumors from a previously reported phase I trial,28 we retrospectively investigated DSG2 and CD46 RNA expression levels in patient tumor samples and their relationship with viral load in blood, and with the number of tumor‐infiltrating leukocytes (TILs). The gene discussed is CD46; the disease is neoplasm.